Text Size

An Open-Label Study of BAL101553 in Adult Patients With Solid Tumors

This study is currently recruiting participants.
Verified November 2012 by Basilea Pharmaceutica
Sponsor:
Information provided by (Responsible Party):
Basilea Pharmaceutica
ClinicalTrials.gov Identifier:
NCT01397929
First received: July 12, 2011
Last updated: November 23, 2012
Last verified: November 2012
History of Changes
  Purpose

First in human, open-label, sequential dose escalation and expansion study of BAL101553 in adult patients with advanced solid tumors.


Condition Intervention Phase
Solid Organ Tumors
 Drug: BAL101553
 Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label Phase I/IIa Study of Intravenous BAL101553 in Adult Patients With Advanced Solid Tumors

Resource links provided by NLM:

MedlinePlus related topics: Cancer
U.S. FDA Resources

Further study details as provided by Basilea Pharmaceutica:

Primary Outcome Measures:
  • To determine the maximum tolerated dose and characterize dose limiting toxicities of BAL101553 [ Time Frame: 28 day cycles ] [ Designated as safety issue: Yes ]
    First-cycle dose limiting toxicities (DLT)


Secondary Outcome Measures:
  • To evaluate safety and tolerability of BAL101553 treatment [ Time Frame: 28 day cycles ] [ Designated as safety issue: Yes ]
    Incidence of adverse events, laboratory abnormalities, clinically significant changes in vital signs or ECG assessments

  • To evaluate BAL101553 pharmacokinetics [ Time Frame: 28 day cycles ] [ Designated as safety issue: No ]
    BAL101553 and BAL27862 PK parameters including (but not limited to): Cmax (maximum observed plasma concentration), AUC (area under the concentration time curve), half-life, volume of distribution

  • To assess anti-tumor activity of BAL101553 [ Time Frame: 28 day cycles ] [ Designated as safety issue: No ]
    Response rate per RECIST guidelines

  • To explore the use of biomarkers and to characterize pharmacodynamic effects of BAL101553 [ Time Frame: 28 day cycles ] [ Designated as safety issue: No ]
    Exploratory assessment of baseline levels and change from baseline in the number of circulating tumor cells and other biomarkers


Estimated Enrollment: 59
Study Start Date: June 2011
Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Drug: BAL101553 Drug: BAL101553
Intravenous administration

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥ 18 years
  2. Patients with confirmed diagnosis of advanced or recurrent solid tumor, who failed standard therapy or for whom no effective standard therapy is available
  3. Measurable tumor disease (or non-measurable prostate or ovarian cancer that can be followed by PSA or CA-125)
  4. Life expectancy ≥ 12 weeks
  5. Acceptable organ and marrow function at baseline (protocol defined laboratory parameters)
  6. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  7. Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

  1. Patients who have received chemotherapy, radiotherapy, immunotherapy, or investigational agents within 4 weeks prior to starting study drug or who have not recovered from side effects of prior therapies
  2. Symptomatic brain metastases (including leptomeningeal disease) indicative of active disease
  3. Peripheral neuropathy ≥ CTCAE v4 grade 2
  4. Uncontrolled intercurrent illness that would unduly increase the risk of toxicity or limit compliance with study requirements
  5. Women who are pregnant or breast-feeding. Men or women of reproductive potential who are not willing to apply effective birth control
  6. Systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg observed as part of the screening examination.
  7. Other protocol-defined exclusion criteria may apply.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01397929

Contacts
Contact: Marc Engelhardt, MD +41 61 567 1546 marc.engelhardt@basilea.com
Contact: Stephanie Anderson +41 61 567 15 24 stephanie.anderson@basilea.com

Locations
United Kingdom
Royal Marsden Hospital Recruiting
Sutton, Surrey, United Kingdom, SM2 5PT
Contact: Rhoda Molife, MD     +44 (0) 208 915 6142     Rhoda.Molife@icr.ac.uk    
Principal Investigator: Rhoda Molife, MD            
University College London NHS Foundation Trust Recruiting
London, United Kingdom, WC1E 2PG
Contact: Rebecca Kristeleit, MD     +44 (0) 2076799279     r.kristeleit@ucl.ac.uk    
Principal Investigator: Rebecca Kristeleit, MD            
Sponsors and Collaborators
Basilea Pharmaceutica
  More Information

No publications provided

Responsible Party: Basilea Pharmaceutica
ClinicalTrials.gov Identifier: NCT01397929     History of Changes
Other Study ID Numbers: CDI-CS-001
Study First Received: July 12, 2011
Last Updated: November 23, 2012
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

ClinicalTrials.gov processed this record on May 22, 2013